Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22361790 | 0.94 | CA2 (0.48) | TSHRCYP3A4KDM4EENPP2MAPK1 | |
| SCHEMBL22361789 | 0.94 | CA2 (0.48) | TSHRCYP3A4KDM4EENPP2MAPK1 | |
| SCHEMBL22419402 | 0.80 | PRSS1 (0.49) | — | |
| SCHEMBL15430 | 0.80 | CYP3A4 (0.70) | TSHRCYP3A4MAPK1TDP1CA2 | |
| SCHEMBL8764209 | 0.77 | P2RY6 (0.50) | TSHRKDM4EENPP2CA2CA1 | |
| Water SCHEMBL28889229 | 0.77 | CYP3A4 (0.67) | TSHRCYP3A4MAPK1TDP1CA2 | |
| Ammonia Solution, Strong SCHEMBL28239770 | 0.77 | CYP3A4 (0.67) | TSHRCYP3A4MAPK1TDP1CA2 | |
| SCHEMBL27741428 | 0.77 | CYP3A4 (0.67) | TSHRCYP3A4MAPK1TDP1CA2 | |
| SCHEMBL3913281 | 0.75 | ENPP2 (0.45) | KDM4EENPP2MAPK1TDP1MGLL | |
| SCHEMBL632310 | 0.73 | CYP3A4 (0.56) | TSHRCYP3A4KDM4EMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| CN-112585147-B | MAP4K4 inhibitors | 帝国理工学院创新有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| CN-112585147-A | MAP4K4 inhibitors | 帝国科技及医学学院 | 2021-03-30 | — | — | CN | disclosed |
| EP-3774797-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | Merck Patent GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2212333-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | TSHR 3368/4885CYP3A4 4172/4885KDM4E 2048/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | TSHR 2661/4885CYP3A4 4721/4885KDM4E 3173/4885 |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 4159/4885CYP3A4 3106/4885KDM4E 772/4885 |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | TSHR 3586/4885CYP3A4 843/4885KDM4E 1987/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | TSHR 3661/4885CYP3A4 1946/4885KDM4E 655/4885 |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | TSHR 2976/4885CYP3A4 788/4885KDM4E 591/4885 |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | TSHR 3306/4885CYP3A4 2011/4885KDM4E 2732/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | TSHR 2661/4885CYP3A4 4721/4885KDM4E 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.